EZM 2302 is primarily utilized in the field of medical research, particularly in the study and development of treatments for various types of cancer. It functions as a potent and selective inhibitor of certain enzymes that play a critical role in the growth and proliferation of cancer cells. By targeting these enzymes, EZM 2302 helps to disrupt the signaling pathways that are essential for tumor survival and progression.

In preclinical studies, EZM 2302 has shown promising results in inhibiting the growth of cancer cells in laboratory models, making it a valuable tool for understanding the mechanisms of cancer and for the development of new therapeutic strategies. Researchers are particularly interested in its potential to be used in combination with other cancer treatments, such as chemotherapy or immunotherapy, to enhance overall efficacy and improve patient outcomes.

Additionally, EZM 2302 is being investigated for its potential applications in other diseases where the targeted enzymes are implicated, such as certain inflammatory and autoimmune conditions. Its ability to selectively inhibit these enzymes without affecting other cellular processes makes it a promising candidate for further development in these areas.